Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Myeloma transplantation: 17p deletions & 4;14 translocations

Nico Gagelmann • 27 Aug 2020
EBMT 2020
Multiple Myeloma

Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the findings from a Chronic Malignancies Working Party European Blood and Marrow Transplant (CMWP-EBMT) study evaluating upfront stem cell transplantation for newly diagnosed multiple myeloma with 17p deletions and 4;14 translocations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nico Gagelmann

0:52
How CAR-T will impact the future of myeloma treatment
Nico Gagelmann • 15 Feb 2024
1:22
The role of splenic irradiation in transplant for patients with myelofibrosis
Nico Gagelmann • 15 Feb 2024
1:41
Predicting outcomes in patients with R/R MM undergoing CAR T-cell therapy: the MyCARe model
Nico Gagelmann • 15 Feb 2024
2:03
Looking to the future in the field of transplantation
Nico Gagelmann • 9 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals